Veracyte's Third Raise Meets A Skeptical Crowd As Prosigna Launch Faces First Test

Veracyte heads into its third-quarter report with an unusual mismatch. Management has raised its full-year revenue outlook twice this year and called the second quarter a milestone, yet the stock has slipped since that report and sentiment has turned noticeably more bearish. The results due after the close on November 4 will show whether the company's growth story still has fuel, or whether the Street's reluctance to fully buy in is justified.

Consensus calls for non-GAAP earnings of $0.44 a share on revenue of about $147.3 million, up roughly 11.7% from the $131.9 million reported a year ago. That is solid growth, but it is a step down from the 15% pace of the second quarter, and the revenue estimate actually sits below the $150.3 million Veracyte posted last quarter. The Earnings Whisper of $0.51 is well above consensus, signaling that the more informed expectation is for a clear beat on profitability. The bigger tell is the full-year math. Management now guides to $590 million to $596 million in revenue, up from $582 million to $592 million, which itself followed an earlier $570 million to $582 million range. Yet full-year consensus of about $583.6 million sits below even the low end of the current guide. Either analysts are building in a cushion for a slowdown, or estimates have not caught up. A quarter near the company's trajectory would make the Street look too conservative.

The core engines matter most here. Decipher, the prostate cancer test, grew revenue 20% last quarter on 17% volume growth and better pricing, with orders per physician hitting a record. Management did trim its full-year Decipher volume expectation by roughly 1,000 tests, concentrated in low-risk active surveillance after a guideline change removed genomic testing from that setting. The company argued pricing would offset the shortfall and keep Decipher revenue growth near 20%. This report should confirm that intermediate and high-risk demand is strong enough to absorb the low-risk drag. If volume decelerates further beyond the low-risk segment, the story of a targeted, guideline-driven blip becomes harder to sustain. Afirma, the thyroid test, is the other swing factor. Its revenue growth guide was lifted to 12% to 14%, helped by a lower no-result rate on its newer transcriptome version. Sustaining double-digit growth would validate that raise.

The newer catalysts are less about third-quarter dollars and more about evidence. The Prosigna breast cancer test launched as a lab-developed test with more than 100 institutions engaged, some weighing a full switch from the incumbent test. Because it lacks Medicare reimbursement, its revenue sits outside guidance and it weighs modestly on gross margin. Updates on order volumes, institutional conversions, progress on electronic health record integration, and the accelerated sales force buildout toward about 15 reps will indicate whether this is a genuine growth leg. Early commentary on TrueMRD for bladder cancer, which launched with Medicare coverage, would add support.

Margins deserve attention too. Adjusted EBITDA margin hit 29.2% last quarter, yet management held its full-year target at above 26%, implying heavier second-half spending on launches. A margin that holds up better than that framework implies would explain the elevated whisper.

The stock trades at $48.20, comfortably above its 200-day moving average of $42.67 and in the upper part of its post-earnings range of $38.25 to $50.17, though not yet pressing that ceiling. It has lagged the S&P 500 by four percentage points since the last report. The central question is simple: can Veracyte show that its core tests are carrying the raised outlook on their own while Prosigna gains real traction? If so, a Street sitting below guidance has room to move up. If Decipher softness spreads, the skeptics will have their argument.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.